I'm sure the CSIRO will be happy with their discounted shares to cover the cost of their encapsulation technology. Activated THC should be relatively stable in dark dry environments so the trail should be a positive. With the Symbion marketing model and product predicted to be available by March we should see some revenue come end of FY. I wouldn't expect much more on Mildura at this stage, scaling back here makes sense until the export market looks more profitable. My target price is $2 by April 1st.
Ann: Commercial-scale GMP medicinal cannabis resin extraction, page-27
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
